Periciazine
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Periciazine: From Psychosis and Severe Behavioural Disturbance to Migraine Disorder
One-Sentence Summary
Periciazine is a phenothiazine antipsychotic (brand name Neulactil), used for schizophrenia and other psychoses and for short-term management of severe anxiety, agitation and impulsive behaviour. The TxGNN model predicts it may be effective for migraine disorder, but this is a computational prediction only, with 0 clinical trials and 0 publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the New Zealand licence data (the approved indication text is empty). Pharmacology reference data describes schizophrenia and other psychoses, and short-term adjunctive management of severe anxiety, psychomotor agitation and violent or dangerously impulsive behaviour |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| New Zealand Market Status | Cancelled only |
| Number of Authorizations | 2 (both cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for periciazine. Based on known information, it is a phenothiazine antipsychotic with dopamine D2 antagonism, plus antihistaminic, anticholinergic and alpha-adrenergic blocking activity. The pharmacology data compiled for this report links it to the dopamine D1 receptor (DRD1), though the source notes that no peer-reviewed data could be found to map a primary molecular target.
Other phenothiazines, such as chlorpromazine and prochlorperazine, are used for acute migraine, mainly for headache and nausea relief through D2 blockade. A class-level mechanistic rationale for periciazine in migraine is therefore plausible. However, no periciazine-specific clinical or literature evidence was found, so the high score remains a model output.
Other predictions in the top six (all L5, all Hold):
| Rank | Predicted Indication | Score | Comment |
|---|---|---|---|
| 2 | Migraine with brainstem aura | 99.84% | A subtype of migraine. The score likely reflects ontology proximity to the parent term, not independent evidence |
| 3 | Atrophoderma vermiculata | 99.36% | No plausible mechanistic link. Likely a knowledge-graph artifact |
| 4 | Dysthymic disorder | 99.25% | Speculative. Periciazine has no established antidepressant role, and older antipsychotics carry a tolerability burden in chronic mood disorders |
| 5 | Migraine with or without aura, susceptibility to | 99.22% | Describes a genetic susceptibility, not a treatable condition, so it is not directly actionable |
| 6 | Ulerythema ophryogenesis | 99.16% | No pharmacological rationale. Likely driven by similarity to other follicular skin disorders |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 254665 | Neulactil | Tab 2.5 mg | Not recorded (licence cancelled) |
| 254673 | Neulactil | Tab 10 mg | Not recorded (licence cancelled) |
Safety Considerations
- Drug Interactions: The interaction query completed with one entry. It is a pharmacology record of periciazine acting on the dopamine D1 receptor, not a drug-drug interaction with a severity level.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN score and a class-level argument from other phenothiazines. There are no trials or publications for periciazine in migraine, and both New Zealand licences are cancelled, so no product is currently marketed.
To proceed, the following is needed:
- Medsafe package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data for periciazine, for example from DrugBank
- Periciazine-specific clinical or literature evidence in migraine, and a comparison with established phenothiazine use
- Confirmation of the original approved indications, as the licence data holds none
- Route and formulation compatibility assessment, and a review of the market and supply situation given the cancelled licences
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.